4/20
10:58 am
rvmd
AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle [Yahoo! Finance]
Low
Report
AACR 2026: Revolution's next prospect, Merck's reveal and a lung cancer battle [Yahoo! Finance]
4/20
09:24 am
rvmd
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $215.00 price target on the stock, up from $170.00.
Medium
Report
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Stifel Nicolaus. They now have a $215.00 price target on the stock, up from $170.00.
4/20
07:41 am
rvmd
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
Medium
Report
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
4/20
07:04 am
rvmd
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
Medium
Report
After a year of turmoil, cancer researchers see promising signs for mRNA vaccines [CNN]
4/19
09:18 pm
rvmd
Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results [Yahoo! Finance]
Low
Report
Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results [Yahoo! Finance]
4/19
02:08 pm
rvmd
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting [Yahoo! Finance]
Low
Report
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting [Yahoo! Finance]
4/19
02:00 pm
rvmd
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Low
Report
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
4/19
12:43 am
rvmd
Jim Cramer Shares Why Revolution Medicines (RVMD) is Extraordinary [Yahoo! Finance]
Low
Report
Jim Cramer Shares Why Revolution Medicines (RVMD) is Extraordinary [Yahoo! Finance]
4/17
04:02 pm
rvmd
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
4/16
10:13 am
rvmd
Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough [TheStreet.com]
Low
Report
Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough [TheStreet.com]
4/16
03:43 am
rvmd
Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data [Yahoo! Finance]
Low
Report
Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data [Yahoo! Finance]
4/15
06:16 am
rvmd
Revolution Medicines prices $2B in concurrent stock, notes offerings [Seeking Alpha]
Medium
Report
Revolution Medicines prices $2B in concurrent stock, notes offerings [Seeking Alpha]
4/15
01:29 am
rvmd
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes [Yahoo! Finance]
Medium
Report
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes [Yahoo! Finance]
4/15
12:41 am
rvmd
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Medium
Report
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
4/14
11:10 am
rvmd
Revolution Medicines (RVMD) had its price target raised by Wells Fargo & Company from $144.00 to $167.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines (RVMD) had its price target raised by Wells Fargo & Company from $144.00 to $167.00. They now have an "overweight" rating on the stock.
4/14
10:16 am
rvmd
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Wedbush. They now have a $147.00 price target on the stock.
Medium
Report
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Wedbush. They now have a $147.00 price target on the stock.
4/14
08:57 am
rvmd
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Evercore Inc.
Medium
Report
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Evercore Inc.
4/14
08:04 am
rvmd
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Medium
Report
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
4/14
08:04 am
rvmd
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Guggenheim.
Medium
Report
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by Guggenheim.
4/14
07:13 am
rvmd
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by HC Wainwright.
Medium
Report
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by HC Wainwright.
4/13
09:08 pm
rvmd
Revolution Medicines (RVMD) Soars to All-Time High on Stellar Cancer Treatment Trial [Yahoo! Finance]
High
Report
Revolution Medicines (RVMD) Soars to All-Time High on Stellar Cancer Treatment Trial [Yahoo! Finance]
4/13
05:01 pm
rvmd
Revolution Medicines shares pop after pancreatic cancer drug trial win [CNBC]
Medium
Report
Revolution Medicines shares pop after pancreatic cancer drug trial win [CNBC]
4/13
04:01 pm
rvmd
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
High
Report
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
4/13
03:56 pm
rvmd
Revolution Medicines (RVMD) had its price target raised by Leerink Partners from $115.00 to $147.00. They now have an "outperform" rating on the stock.
Low
Report
Revolution Medicines (RVMD) had its price target raised by Leerink Partners from $115.00 to $147.00. They now have an "outperform" rating on the stock.
4/13
12:08 pm
rvmd
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Low
Report
Revolution Medicines (RVMD) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..